Guggenheim Reiterates Buy Rating on Travere Therapeutics (TVTX)
Guggenheim maintains its buy rating on Travere Therapeutics with a $65 price target, a 10.45% upside from the current price.
Key Points
- Guggenheim analyst Vamil Divan reiterated a buy rating on Travere Therapeutics, Inc. (TVTX) with a $65 price target on June 25, 2026.
- Guggenheim's $65 price target implies 10.45% upside from Travere Therapeutics, Inc.'s ($TVTX) current $58.85 share price.
- Shares of Travere Therapeutics traded near $57.69 on Thursday, with a market cap of approximately $5.12 billion and a forward P/E of 11.36.
- Several insiders sold shares in June 2026, and analysts from multiple firms maintain a buy rating with targets as high as $70.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim analyst Vamil Divan reaffirmed a buy rating for Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 25, 2026. The firm set a price target of $65, indicating confidence in the company's future performance. Shares of Travere traded near $57.69 on Thursday.
Travere Therapeutics, Inc. Stock Down 10.4%
Shares of Travere Therapeutics, Inc. traded near $57.69 on Thursday. The company has a market capitalization of about $5.12 billion and a forward P/E ratio of 11.36. With a beta of 1.141, the stock has shown some volatility. Its 52-week range spans from a low of $13.97 to a high of $56.81. The stock's 50-day moving average is approximately $43.80, and its 200-day moving average is around $33.62. Travere's current ratio is 3.131, and its quick ratio is 2.816, while its debt-to-equity ratio stands at 331.884.
$TVTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Travere Therapeutics, Inc.
In June 2026, several insiders at Travere Therapeutics engaged in stock transactions. Chief Medical Officer Jula Inrig sold 468 shares on June 22. On June 12, Roy Baynes sold 4,500 shares at an average price of $50.00 under a planned sale, while also buying 4,500 shares at $21.38. Timothy Coughlin sold 10,000 shares and also bought 10,000 shares on the same day at $26.52.
Analysts Set New Price Targets
On June 25, 2026, Guggenheim reiterated its buy rating for Travere Therapeutics with a $65 price target. Other analysts have also shown optimism, with Wedbush maintaining a buy rating and a $61 target on June 22, and Evercore ISI Group holding a buy rating with a $60 target on June 18. Citigroup, on June 15, set a target of $70 while maintaining its buy rating. Overall, the consensus recommendation is a strong buy, with an average target price of $57.29 from 14 analysts.
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing and delivering therapies for rare kidney and metabolic diseases. The company's products include FILSPARI and Thiola, which target conditions like IgA Nephropathy and cystinuria, respectively. Travere is also working on clinical-stage programs such as Sparsentan and Pegtibatinase. Led by CEO Dr. Eric M. Dube, the company employs 497 people.
Bottom Line
Guggenheim's reiterated buy rating and $65 price target reflect confidence in Travere Therapeutics' potential. Investors track such ratings closely, as they can influence market sentiment. It's important to remember that analyst ratings are based on past data and projections, and actual performance may vary.
Get Travere Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TVTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.